SCHEMBL698878

SCHEMBL698878

O=C(Cl)c1nccnc1C(=O)Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.37
ADORA3 P0DMS8 1/20 0.37
MC4R P32245 1/20 0.37
ADRA1A P35348 1/20 0.37
MC3R P41968 1/20 0.37
PRKCI P41743 4/20 0.36
ATR Q13535 1/20 0.36
KDM4E B2RXH2 5/20 0.36
MAPT P10636 3/20 0.36
ALDH1A1 P00352 3/20 0.36
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36
BLM P54132 1/20 0.36
AGER Q15109 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SIRT6 Q8N6T7 1/20 0.36
GRM5 P41594 1/20 0.34
P2RX7 Q99572 2/20 0.33
NAPRT Q6XQN6 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13697278 0.89 PDE3B (0.39) TSHRADORA3MC4RADRA1AMC3R
SCHEMBL4569355 0.87 PRKCI (0.47) PRKCIATRKDM4EL3MBTL1GRM5
SCHEMBL1452735 0.84 SMN1; SMN2 (0.39) TSHRKDM4EMAPTALDH1A1CYP3A4
SCHEMBL23032651 0.82 KDM4E (0.34) TSHRPRKCIKDM4EMAPTALDH1A1
SCHEMBL30801476 0.77 HTT (0.37) TSHRKDM4EMAPTALDH1A1CYP3A4
SCHEMBL629620 0.77 HTT (0.37) TSHRKDM4EMAPTALDH1A1CYP3A4
SCHEMBL17674836 0.77 MAPT (0.36) TSHRKDM4EMAPTL3MBTL1CYP1A2
SCHEMBL2492969 0.75 TSHR (0.48) TSHRADORA3MC4RADRA1AMC3R
SCHEMBL890368 0.73 KDM4E (0.55) TSHRKDM4EMAPTALDH1A1CYP3A4
SCHEMBL22118239 0.73 KMO (0.38) TSHRPRKCIKDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118667229-A Preparation method of composite flame-retardant material 华南理工大学 2024-09-20 CN claimed
US-20250376543-A1 HYALURONIC ACID-COLLAGEN COPOLYMER COMPOSITIONS AND MEDICAL APPLICATIONS THEREOF SHANGHAI QISHENG BIOLOGICAL PREPARATION CO LTD (CN) 2025-12-11 US disclosed
US-12304974-B2 Hyaluronic acid-collagen copolymer compositions and medical applications thereof SHANGHAI QISHENG BIOLOGICAL PREPARATION CO., LTD. (CN) 2025-05-20 US disclosed
CN-118667229-B Preparation method of composite flame-retardant material 华南理工大学 2025-03-28 CN disclosed
CN-118874816-A High-temperature-resistant metal sealing gasket processing technology 锦州光和密封实业有限公司 2024-11-01 CN disclosed
CN-118667229-A Preparation method of composite flame-retardant material 华南理工大学 2024-09-20 CN disclosed
CN-118667229-A Preparation method of composite flame-retardant material 华南理工大学 2024-09-20 CN disclosed
WO-2024163315-A2 DERIVATIZED COLLAGEN-HYALURONIC ACID BASED IMPLANTS FOR SUSTAINED DELIVERY OF OPHTHALMIC DRUGS DEVORE DALE (US) 2024-08-08 WO disclosed
US-20240252446-A1 DERIVATIZED COLLAGEN-HYALURONIC ACID BASED IMPLANTS FOR SUSTAINED DELIVERY OF OPHTHALMIC DRUGS SUSTAINED DRUG DELIVERY LLC 2024-08-01 US disclosed
WO-2023125689-A1 HYALURONIC ACID-COLLAGEN COPOLYMER COMPOSITIONS AND MEDICAL APPLICATIONS THEREOF SHANGHAI QISHENG BIOLOGICAL PREPARATION CO., LTD. (CN) 2023-07-06 WO disclosed
US-20120088908-A1 Prodrugs Based on Gemcitabine Structure and Synthetic Methods and Applications Thereof SANLUGEN PHARMATECH LTD. (CN) 2012-04-12 US disclosed
EP-2423215-A1 PRODRUGS BASED ON GEMCITABINE STRUCTURE AS WELL AS SYNTHETIC METHOD AND APPLICATION THEREOF Sanlugen Pharmatech Ltd. (CN) 2012-02-29 EP disclosed
WO-2011104266-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-09-01 WO disclosed
US-20110206690-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-08-25 US disclosed
CN-1747955-A Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, method for the production and use thereof as medicaments SANOFI AVENTIS DEUTSCHLAND (DE) 2006-03-15 CN disclosed
EP-0214853-B1 Viscoelastic collagen solution for ophthalmic use and method of preparation MINNESOTA MINING & MFG (US) 1994-11-30 EP disclosed
US-4883864-A COUPLED AND FREE AMINE GROUPS CAPPED WITH UREA OR AMIDE GROUPS, EYE SURGERY MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1989-11-28 US disclosed
US-4851513-A Viscoelastic collagen solution for opthalmic use and method of preparation MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1989-07-25 US disclosed
US-4713446-A COLLAGEN COUPLED TO CARBONYL OR SULFONYL GROUPS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1987-12-15 US disclosed
EP-0214853-A2 Viscoelastic collagen solution for ophthalmic use and method of preparation MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1987-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088908-A1 Prodrugs Based on Gemcitabine Structure and Synthetic Methods and Applications Thereof TYMP, DCTD, GLS2 TSHR 4200/4885ADORA3 581/4885MC4R 4713/4885
US-20110206690-A1 DIMERIC IAP INHIBITORS XIAP, BIRC5, BIRC2 TSHR 4630/4885ADORA3 4712/4885MC4R 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.